Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma - Contacts and Locations

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

This study has been completed.

Study NCT00002745. Last updated on November 29, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002745

Locations


United States, District of Columbia
	Walter Reed Army Medical Center
	Washington, District of Columbia, United States, 20307-5000

United States, Minnesota
	University of Minnesota Cancer Center
	Minneapolis, Minnesota, United States, 55455

United States, Missouri
	Washington University Barnard Cancer Center
	Saint Louis, Missouri, United States, 63110

United States, New Jersey
	Cooper Cancer Institute
	Camden, New Jersey, United States, 08103
	St. Joseph's Hospital and Medical Center
	Paterson, New Jersey, United States, 07503

Sponsors and Collaborators

Cancer and Leukemia Group B

National Cancer Institute (NCI)

Investigators


Study Chair:	Nancy L. Bartlett, MD	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis